Latest Period
Q1 2026
Security Snapshot
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) Institutional Ownership
CUSIP: 23284F105
13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026
Institutions Reporting
179
Shares (Excl. Options)
193,169,653
Price
$4.70
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.00001 par value per share ("Common Stock")
- Symbol
- CTMX on Nasdaq
- Shares outstanding
- 217,079,600
- Price per share
- $4.30
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 193,169,653
- Total reported value
- $907,862,078
- % of total 13F portfolios
- 0%
- Share change
- +46,088,761
- Value change
- +$226,816,911
- Number of holders
- 179
- Price from insider filings
- $4.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") is tracked under CUSIP 23284F105.
- 179 institutions reported positions in Q1 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 122 to 179 between Q4 2025 and Q1 2026.
- Reported value moved from $613,664,738 to $907,862,078.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 179 institutions filings for Q1 2026.
Security key
23284F105
Latest holder period
Q1 2026
13F holders
179
13D/G owners
9
CIK / CUSIP context first
Open Q1 2026 holders
CTMX full holder history
CytomX Therapeutics, Inc. SEC filings
CytomX Therapeutics, Inc. company facts
CytomX Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23284F105:
Significant Owners of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +18% | $105,171,344 | +$17,756,285 | 24,688,109 | +20% | FMR LLC | 31 Dec 2025 |
| Longitude Capital Partners V, LLC | 7% | -4.3% | $65,740,382 | +$16,125,000 | 15,288,461 | +33% | Patrick G. Enright | 31 Mar 2026 |
| Point72 Asset Management, L.P. | 5% | +83% | $51,063,531 | +$31,941,228 | 10,864,581 | +167% | Point72 Asset Management, L.P. | 15 Apr 2026 |
| PERCEPTIVE ADVISORS LLC | 4.6% | -22% | $43,424,943 | +$1,800,148 | 10,098,824 | +4.3% | Perceptive Advisors LLC | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | -53% | $42,923,133 | -$23,991,317 | 9,982,124 | -36% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 3.5% | -47% | $17,250,001 | -$17,250,001 | 5,769,231 | -50% | BVF PARTNERS L P/IL | 03 Jul 2025 |
| ORBIMED ADVISORS LLC | 2.1% | -66% | $15,160,295 | -$21,224,155 | 3,525,650 | -58% | OrbiMed Advisors LLC | 31 Dec 2025 |
| Seven Fleet Capital Management LP | 0.5% | $4,667,211 | +$4,456,950 | 1,085,398 | +2120% | Seven Fleet Master Fund LP | 31 Mar 2026 | |
| Seven Fleet Partners LP | 0.2% | $267,784 | 377,161 | Seven Fleet Partners LP | 13 May 2025 |
As of 31 Mar 2026, 179 institutional investors reported holding 193,169,653 shares of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX). This represents 89% of the company’s total 217,079,600 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 31,955,637 | +29% | 0.01% | $150,191,494 |
| Kynam Capital Management, LP | 6.9% | 15,013,093 | +67% | 4.5% | $70,561,537 |
| BANK OF AMERICA CORP /DE/ | 4.7% | 10,202,785 | +1064% | 0% | $47,953,089 |
| PERCEPTIVE ADVISORS LLC | 4.7% | 10,098,824 | +4.3% | 0.94% | $47,464,473 |
| Venrock Adviser, LLC | 4.6% | 9,982,124 | -36% | 1.8% | $46,915,983 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 8,733,118 | 0% | 0% | $41,045,655 |
| Point72 Asset Management, L.P. | 3.6% | 7,875,390 | +52% | 0.06% | $37,014,333 |
| STATE STREET CORP | 2.6% | 5,663,408 | +10% | 0% | $26,618,018 |
| CITADEL ADVISORS LLC | 2.5% | 5,406,193 | +1479% | 0.02% | $25,409,107 |
| BlackRock, Inc. | 2.4% | 5,228,280 | +42% | 0% | $24,572,917 |
| BAKER BROS. ADVISORS LP | 2.3% | 4,975,826 | +17% | 0.13% | $23,386,382 |
| Elmind Capital, LP | 2.1% | 4,550,000 | +550% | 6.1% | $21,385,000 |
| Nextech Invest, Ltd. | 2% | 4,449,932 | 1.5% | $20,914,680 | |
| MARSHALL WACE, LLP | 1.9% | 4,138,176 | +258% | 0.02% | $19,449,427 |
| MILLENNIUM MANAGEMENT LLC | 1.7% | 3,660,190 | +1164% | 0.01% | $17,202,893 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.7% | 3,582,985 | 0% | $16,840,029 | |
| Siren, L.L.C. | 1.6% | 3,457,711 | 0.45% | $16,251,242 | |
| ADAR1 Capital Management, LLC | 1.6% | 3,410,190 | -18% | 0.97% | $16,027,893 |
| Eversept Partners, LP | 1.5% | 3,188,514 | +27% | 0.99% | $14,986,016 |
| UBS Group AG | 1.4% | 3,120,155 | +742% | 0% | $14,664,729 |
| Jefferies Financial Group Inc. | 1.4% | 3,067,864 | +12810% | 0.18% | $14,418,961 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 2,710,156 | +74% | 0.01% | $12,737,733 |
| Qube Research & Technologies Ltd | 1% | 2,249,583 | +112% | 0.02% | $10,573,040 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.95% | 2,066,612 | +35% | 0% | $9,718,261 |
| Woodline Partners LP | 0.92% | 2,000,825 | -14% | 0.04% | $9,403,878 |
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share ("Common Stock") (CTMX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 193,169,653 | $907,862,078 | +$226,816,911 | $4.70 | 179 |
| 2025 Q4 | 144,051,943 | $613,664,738 | +$47,313,431 | $4.26 | 122 |
| 2025 Q3 | 137,411,371 | $438,342,190 | +$24,527,196 | $3.19 | 102 |
| 2025 Q2 | 133,305,109 | $302,602,132 | +$213,797,054 | $2.27 | 82 |
| 2025 Q1 | 45,180,958 | $28,723,084 | -$1,507,772 | $0.64 | 63 |
| 2024 Q4 | 46,714,805 | $48,111,898 | -$6,381,441 | $1.03 | 68 |
| 2024 Q3 | 51,193,741 | $60,427,306 | +$480,690 | $1.18 | 69 |
| 2024 Q2 | 50,687,257 | $61,863,474 | +$334,609 | $1.22 | 73 |
| 2024 Q1 | 44,548,308 | $97,118,414 | +$26,024,246 | $2.18 | 85 |
| 2023 Q4 | 32,640,376 | $50,592,909 | +$410,206 | $1.55 | 66 |
| 2023 Q3 | 32,393,313 | $41,785,804 | -$2,418,556 | $1.29 | 61 |
| 2023 Q2 | 34,120,916 | $58,688,106 | -$2,378,087 | $1.72 | 66 |
| 2023 Q1 | 35,594,054 | $53,751,153 | -$933,381 | $1.51 | 74 |
| 2022 Q4 | 35,979,014 | $120,192,376 | -$724,794 | $1.60 | 77 |
| 2022 Q3 | 36,281,610 | $52,604,898 | -$18,986,577 | $1.45 | 76 |
| 2022 Q2 | 45,579,430 | $83,410,352 | -$17,825,825 | $1.83 | 86 |
| 2022 Q1 | 53,661,262 | $143,355,949 | -$1,754,233 | $2.67 | 112 |
| 2021 Q4 | 54,342,875 | $235,299,521 | -$5,313,006 | $4.33 | 106 |
| 2021 Q3 | 53,978,233 | $274,775,521 | -$17,338,127 | $5.09 | 111 |
| 2021 Q2 | 56,688,576 | $358,879,555 | +$4,313,452 | $6.33 | 119 |
| 2021 Q1 | 54,613,642 | $422,156,729 | +$130,257,296 | $7.73 | 123 |
| 2020 Q4 | 37,995,365 | $248,881,255 | +$5,576,359 | $6.55 | 123 |
| 2020 Q3 | 36,841,081 | $245,069,950 | -$11,639,890 | $6.65 | 128 |
| 2020 Q2 | 37,758,348 | $314,514,192 | +$15,532,613 | $8.33 | 133 |
| 2020 Q1 | 36,087,916 | $276,879,388 | +$244,869 | $7.67 | 113 |
| 2019 Q4 | 36,001,618 | $299,160,261 | -$9,333,104 | $8.31 | 119 |
| 2019 Q3 | 35,837,109 | $264,433,175 | -$1,377,891 | $7.38 | 111 |
| 2019 Q2 | 35,647,194 | $399,598,509 | -$8,094,164 | $11.22 | 108 |
| 2019 Q1 | 36,897,584 | $396,629,592 | -$12,805,896 | $10.75 | 110 |
| 2018 Q4 | 37,768,617 | $569,884,178 | -$2,745,916 | $15.10 | 108 |
| 2018 Q3 | 37,780,542 | $697,391,587 | +$95,602,749 | $18.50 | 119 |
| 2018 Q2 | 32,308,752 | $738,633,935 | +$66,042,910 | $22.86 | 139 |
| 2018 Q1 | 28,622,740 | $814,197,912 | +$73,379,749 | $28.45 | 136 |
| 2017 Q4 | 30,146,848 | $636,945,631 | +$56,049,834 | $21.11 | 119 |
| 2017 Q3 | 24,242,512 | $440,733,363 | +$42,038,227 | $18.17 | 97 |
| 2017 Q2 | 22,105,676 | $342,719,825 | +$44,092,931 | $15.50 | 89 |
| 2017 Q1 | 19,204,130 | $331,600,145 | +$58,337,064 | $17.27 | 86 |
| 2016 Q4 | 16,857,707 | $185,279,386 | +$14,954,410 | $10.99 | 68 |
| 2016 Q3 | 19,725,140 | $242,759,481 | +$18,076,577 | $15.68 | 61 |
| 2016 Q2 | 18,845,409 | $149,178,103 | +$16,034,432 | $10.21 | 59 |
| 2016 Q1 | 12,778,869 | $164,816,000 | +$3,379,204 | $12.90 | 47 |
| 2015 Q4 | 12,469,279 | $258,260,359 | +$239,918,359 | $20.87 | 47 |